Published in the International Journal of Obesity, University of Minnesota Medical School and School of Public Health researchers led a study on the relationship between dietary intake and cardiovascular disease risk factors.
Does an Additional First-Line Option Alter Approach in EGFR-Mutant NSCLC?
In August, the FDA approved another first-line treatment option for patients with EGFR-mutant non-small cell lung cancer (NSCLC): the third-generation EGFR tyrosine kinase inhibitor (TKI)
November 2, 2024